Article
Oncology
Rebecca Rootwelt Winther, Eva Skovlund, Joakim Stray Andreassen, Lisa Arvidsson, Jonathan Halvardson, Ole Solheim, Jiri Bartek, Stein Kaasa, Marianne Jensen Hjermstad, Einar Osland Vik-Mo
Summary: Metastases to the brain are serious and often fatal. This study identified factors that predict survival after surgery for these metastases, and created a prognostic index to guide decision-making. The index was validated on patients from other hospitals and found to be effective.
Article
Oncology
Minmin Li, Yanbo Song, Longhao Li, Jian Qin, Hongbin Deng, Tao Zhang
Summary: The case report presented a patient with multiple BMs of NSCLC, who received two courses of WBRT and one course of GK radiotherapy over 5 years. The patient survived for 12 years with good tumor response to each radiotherapy, maintaining a high quality of life throughout the survival period.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Hanming Li, Wang Li, Chao Qi, Lu Zhou, Fengyun Wen, Yanli Qu, Hong Yu
Summary: This study demonstrated that compared to WBRT alone, WBRT + boost improved overall survival (OS) and intracranial progression-free survival (iPFS) in small cell lung cancer (SCLC) patients with brain metastasis. A higher biologically effective dose (BED) (>58.35 Gy) in the WBRT + boost group was significantly associated with improved OS and iPFS compared to a lower BED (<= 58.35 Gy).
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Salvador Gutierrez Torres, Federico Maldonado Magos, Jenny G. Turcott, Juan-Manuel Hernandez-Martinez, Bernardo Cacho-Diaz, Andres F. Cardona, Aida Mota-Garcia, Francisco Lozano Ruiz, Maritza Ramos-Ramirez, Oscar Arrieta
Summary: This study aimed to identify prognostic factors associated with survival after brain re-irradiation to develop a new prognostic index. The independent prognostic factors for shorter survival after re-irradiation were identified as age >50 years, uncontrolled primary tumor, lesion size >20mm, and an interval <12 months between radiation treatments. The new brain re-irradiation index (BRI) can be easily implemented for prognostic classification of cancer patients with progressive or recurrent brain metastases.
Article
Oncology
Ji Zhang, Juebin Jin, Yao Ai, Kecheng Zhu, Chengjian Xiao, Congying Xie, Xiance Jin
Summary: This study developed a radiomics nomogram to predict the survival of brain metastasis patients from non-small cell lung cancer who underwent whole brain radiotherapy, based on CT images and clinical factors. The nomogram showed good performance in predicting short-term and long-term survival, with high concordance index and area under curve.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biology
Dirk Rades, Leonie Johannwerner, Elisa M. Werner, Florian Cremers, Nathan Y. Yu
Summary: A model was developed to predict survival after WBRT+SIB for cerebral metastases. Three models, each including three prognostic groups, were created and compared. Model 2, considering KPS, lesions, and age, showed better accuracy in predicting survival >= 6 months compared to Model 1. Patients with poor prognosis may not benefit from SIB.
Article
Oncology
Valeria Interno, Maria Chiara Sergi, Maria Elvira Metta, Michele Guida, Paolo Trerotoli, Sabino Strippoli, Salvatore Circelli, Camillo Porta, Marco Tucci
Summary: This study retrospectively analyzed the impact of clinical-pathological features and multimodal therapies on the overall survival of patients with melanoma brain metastases. The results showed that encephalic radiotherapy significantly improved survival, but not for patients with LDH levels higher than two times the upper limit normal. These findings can help guide therapeutic strategies for patients in the worst prognostic subgroup of melanoma brain metastases.
Article
Oncology
Xue-Yi Xie, Hong-Hua Peng, Xi Zhang, Yu-Liang Pan, Zhen Zhang, Pei-Guo Cao
Summary: This study evaluated the clinical outcomes of hypofractionated stereotactic radiotherapy (HFSRT) combined with whole brain radiotherapy (WBRT) in patients with brain metastases (BMs). The results showed that this treatment modality has a high success rate in achieving intracranial local control without severe acute toxicities. Factors such as KPS score and tumor volume significantly influenced the overall survival rate.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Tian-Qi Du, Xiang Li, Wei-Si Zhong, Jian-Dong Tian, Yu-Xia Zhao, Dan Liu
Summary: For patients with brain metastasis of lung cancer, SIB-IMRT may be associated with a more favorable prognosis.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Joanna Kufel-Grabowska, Anna Niwinska, Barbara S. Radecka, Shan Ali, Tomasz Mandat, Renata Duchnowska
Summary: Prognostic tools for breast cancer patients with brain metastases include performance status, age at BM diagnosis, number of BM, primary tumor phenotype/genotype, and extracranial metastases status, but with varying specific cut-off values.
Article
Oncology
Naoyuki Kanayama, Toshiki Ikawa, Shingo Ohira, Takero Hirata, Masahiro Morimoto, Kazuhiko Ogawa, Teruki Teshima, Koji Konishi
Summary: This study demonstrates that a significant reduction in brain metastases volume at 6 months post-SRT can predict local control. The dose of 80% of the gross tumor volume (GTV) D80 in the LQ model: alpha/beta = 20 may be a predictive factor for volume reduction.
Article
Medicine, General & Internal
Matthias Schneider, Niklas Schaefer, Christian Bode, Valeri Borger, Lars Eichhorn, Frank A. Giordano, Erdem Gueresir, Muriel Heimann, Yon-Dschun Ko, Felix Lehmann, Anna-Laura Potthoff, Alexander Radbruch, Christina Schaub, Katjana S. Schwab, Johannes Weller, Hartmut Vatter, Ulrich Herrlinger, Jennifer Landsberg, Patrick Schuss
Summary: Studying preoperative laboratory inflammation markers in melanoma patients with brain metastasis undergoing surgery revealed that elevated CRP levels, higher NLR and PLR, and lower LMR were associated with reduced overall survival rates. These markers could potentially be integrated into preoperative treatment planning for affected patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Yong Bae Kim, Jee Suk Chang, Doo Ho Choi, Haeyoung Kim, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, In Ah Kim
Summary: The study investigated the outcomes of salvage whole-brain radiotherapy for recurrent brain metastases from breast cancer, identified prognostic factors for overall survival, and proposed a novel prognostic classification. Factors such as time before salvage WBRT, control of primary cancer or extracranial metastases, systemic treatment, and dosage of WBRT were found to impact overall survival significantly. A new RPA classification based on these factors showed distinct differences in survival outcomes among different classes.
Article
Oncology
Cecilia Jiang, Troy J. Kleber, Jeffrey M. Switchenko, Mohammad K. Khan
Summary: This study retrospectively reviewed 63 MBM patients treated with WBRT at a single institution from 2000 to 2018, finding that WBRT remains an effective treatment strategy for controlling intracranial disease with limited treatment-related toxicities. Performance status and the use of BRAF inhibitors were associated with overall survival, highlighting the potential impact of systemic therapy in improving outcomes for MBM patients.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Dirk Rades, Leonie Johannwerner, Elisa M. Werner, Florian Cremers, Jan Gliemroth, Nathan Y. Yu
Summary: This study compared the effectiveness of whole-brain radiotherapy (WBRT) alone and WBRT combined with simultaneous integrated boost (WBRT+SIB) for unresected brain metastases. The results showed that WBRT+SIB improved intracerebral control (IC) compared to WBRT alone, but overall survival (OS) was similar between the two treatments. Selected patients with a high risk of intracerebral recurrence may benefit from WBRT+SIB.
ANTICANCER RESEARCH
(2023)